DR. E. SHILPALAKSHMI PRASAD,DR. PARIMALA A
DOI: https://doi.org/Background: The levonorgestrel intrauterine device (LNG-IUS) is generally regarded as a primary, minimally invasive intervention for heavy menstrual bleeding (HMB), providing both therapeutic effectiveness and contraceptive advantages. Even though it has a good safety record and works well to cut down on menstrual blood loss, treatment failure and problems can happen from time to time, which is why doctors need to be extra careful.
Case Presentation: We describe a series of cases involving women with heavy menstrual bleeding (HMB) who had the insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS) but exhibited varied results, including insufficient bleeding control, intolerance, or the need for other therapies. Clinical evaluations, follow-up trends, and treatment strategies underscore the variability of responses to LNG-IUS therapy.
Discussion: Although LNG-IUS continues to be extremely beneficial for the majority of patients with HMB, this study highlights that some subgroups may not see prolonged benefits. Possible explanations include underlying uterine disease, difficulties with the device, or differences in how each person responds to hormones. These findings are consistent with the current literature, indicating that a certain group of patients may require further treatment or surgical intervention. Recognizing treatment failure early is important to avoid delays in therapy and avoidable illness.
Conclusion: This series of cases shows how important it is to do tailored evaluations, keep a close eye on patients, and quickly find out when LNG-IUS fails in the treatment of HMB.
